Overview

Proof of Mechanism in ELT

Status:
Completed
Trial end date:
2009-12-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline